Selected article for: "blood cell and cell line"
Author: Okur, Hacer Kuzu; Yalcin, Koray; Tastan, Cihan; Demir, Sevda; Yurtsever, Bulut; Sir, Gozde; Kancagi, Derya Dilek; Abanuz, Selen; Seyis, Utku; Zengin, Rehile; Hemsinlioglu, Cansu; Kara, Mujdat; Yildiz, Mehmet Erdem; Deliceo, Elif; Birgen, Nur; Pelit, Nil Banu; Cuhadaroglu, Caglar; Kocagoz, Ayse Sesin; Ovali, Ercument
Title: Preliminary report of In vitro and In vivo Effectiveness of Dornase alfa on SARS-CoV-2 infection
  • Cord-id: x10bbv7y
  • Document date: 2020_9_7
    • ID: x10bbv7y
    Snippet: Dornase alfa, the recombinant form of the human DNase I enzyme, breaks down neutrophil extracellular traps (NET) that include a vast amount of DNA fragments, histones, microbicidal proteins and oxidant enzymes released from necrotic neutrophils in the highly viscous mucus of cystic fibrosis patients. Dornase alfa has been used for decades in patients with cystic fibrosis to reduce the viscoelasticity of respiratory tract secretions, to decrease the severity of respiratory tract infections, and t
    Document: Dornase alfa, the recombinant form of the human DNase I enzyme, breaks down neutrophil extracellular traps (NET) that include a vast amount of DNA fragments, histones, microbicidal proteins and oxidant enzymes released from necrotic neutrophils in the highly viscous mucus of cystic fibrosis patients. Dornase alfa has been used for decades in patients with cystic fibrosis to reduce the viscoelasticity of respiratory tract secretions, to decrease the severity of respiratory tract infections, and to improve lung function. Previous studies have linked abnormal NET formations to lung diseases, especially to acute respiratory distress syndrome (ARDS). It is well known that novel Coronavirus disease 2019 (COVID-19) pneumonia progresses to ARDS and even multiple organ failure. High blood neutrophil levels are an early indicator of COVID-19 and predict severe respiratory diseases. Also it is reported that mucus structure of COVID-19 is very similar to cystic fibrosis due to the accumulation of excessive NET in the lungs. In this study, we showed the recovery of three COVID-19 patients after including Dornase alfa in their treatment. We followed clinical improvement in the radiological analysis (2-of-3 cases), oxygen saturation (SpO2), respiratory rate, disappearing of dyspnea, coughing and a decrease in NET formation and SARS-CoV-2 viral load after the treatment. Also here, we share our preliminary results suggesting that Dornase alfa has an anti-viral effect against SARS-CoV-2 infection in a green monkey kidney cell line, Vero, and a bovine kidney cell line, MDBK without determined cytotoxicity on healthy peripheral blood mononuclear cells.

    Search related documents:
    Co phrase search for related documents
    • accumulation neutrophil infiltration and acute respiratory: 1, 2
    • activation marker and acute ards respiratory distress syndrome: 1, 2
    • activation marker and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • activation marker and lymphocyte activation: 1, 2
    • acute ards respiratory distress syndrome and add therapy: 1
    • acute ards respiratory distress syndrome and admission fever: 1, 2, 3
    • acute ards respiratory distress syndrome and low severity: 1, 2, 3
    • acute respiratory and add therapy: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory and admission dyspneic: 1
    • acute respiratory and admission fever: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and low severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lymphocyte activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • admission fever and low severity: 1
    • low severity and lymphocyte activation: 1